Should You Buy, Sell or Hold Lilly Stock Ahead of Q2 Earnings?

Eli Lilly (LLY) is set to report Q2 earnings on August 7th, with sales and EPS estimated at $14.75 billion and $5.61, respectively, primarily driven by robust demand for its GLP-1 drugs, Mounjaro and Zepbound, alongside contributions from recent product launches and pipeline advancements. Despite facing pricing pressures and intensifying competition in the GLP-1 market, highlighted by Novo Nordisk's recent guidance reduction, Lilly's strategic focus on its flagship therapies, ongoing M&A activities, and diversification into new therapeutic areas like cardiovascular and oncology are expected to underpin its continued growth trajectory, justifying its premium valuation.

Analysis

Eli Lilly (LLY) approaches its Q2 earnings release on August 7 with consensus estimates at $14.75 billion in sales and $5.61 in EPS. The company's growth trajectory is heavily reliant on its GLP-1 franchise, with Mounjaro and Zepbound expected to report combined sales of approximately $7.7 billion, accounting for over 50% of total revenue due to improved supply and international market expansion. This top-line strength is contrasted by significant headwinds, including sustained pricing pressure across its portfolio, with a mid-to-high single-digit price decline anticipated for 2025, and cannibalization of older products like Trulicity. Furthermore, the competitive environment is intensifying; a recent guidance reduction from key competitor Novo Nordisk (NVO) cited increased market pressure, impacting LLY's stock, while Amgen (AMGN) and Viking Therapeutics (VKTX) advance their own late-stage candidates. Lilly is actively countering these threats by progressing its next-generation obesity pipeline and diversifying through M&A into cardiovascular and oncology. Despite trading at a premium valuation and having a mixed recent earnings surprise history, a positive Earnings ESP of +0.18% suggests a potential for an earnings beat.

Key Decisions for Investors

• Investors should scrutinize the upcoming Q2 sales figures for Mounjaro and Zepbound against consensus estimates of $4.58 billion and $3.1 billion, respectively, as any shortfall could challenge the stock's premium valuation.
• Pay close attention to management's commentary on the competitive landscape, particularly the impact of dynamics cited in Novo Nordisk's guidance cut, and any revisions to the forecast for realized drug prices and operating margins.
• Given the high valuation, the investment thesis relies on sustained long-term growth; therefore, evaluate the progress of Lilly's pipeline diversification and M&A strategy as a crucial hedge against the single-point risk of the hyper-competitive GLP-1 market.